nivolumab,ipilimumab,cabozantinib
astrazeneca,bms,ipsen
['gu ', 'ipi/', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'prospect data', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabopoint', 'cabo ', 'nivo', ' uc,(-ucsd),(-ucsf),', 'ipsen']
cabopoint prospectively explores cabo in ici refactory disease. rr of 30% post ipi/nivo and 25% post vegf/ici therapy show sequencing these agents is of benifit. it strengthens the data for cabo in this setting which joins axi and pazo with prospect data in this setting. #gu23 
Interested in Urology Cancers, biomarkers and drug development.